Scholarlink

Background <p>Gout, an inflammatory arthritis characterized by monosodium urate crystal deposition, affects 1–4% of the global population and demonstrates strong associations with metabolic syndrome. Metabolic dysfunction-associated fatty liver disease (MASLD), affecting 38% of adults worldwide, represents a multisystem disorder with substantial morbidity and mortality. This first European prospective cohort study systematically examines the association between MASLD and incident gout risk.</p> Method <p>Utilizing UK Biobank data (<i>n</i> = 402,083 after exclusions), we conducted a prospective cohort analysis excluding participants with baseline gout, arthritis, hepatitis B/C, alcohol-related liver disease, or events within the initial 2-year follow-up. Cox proportional hazards models evaluated MASLD–gout associations, with Kaplan–Meier curves illustrating cumulative incidence.</p> Result <p>MASLD patients exhibited a 71% elevated gout risk versus non-MASLD counterparts (HR = 1.71, 95% CI 1.59–1.83,&#xa0;<i>P</i> &lt; 0.0001). Subgroup analyses revealed consistent associations across demographics, with attenuated risk in older adults (≥ 65&#xa0;years: HR = 1.55 vs. &lt; 65&#xa0;years: HR = 1.86). Paradoxically, individuals without diabetes, hypertension, or central obesity demonstrated a higher gout risk than those with these comorbidities. MASLD patients showed significantly greater cumulative gout incidence over time (<i>P</i> &lt; 0.001).</p> Conclusion <p>MASLD independently associates with increased gout risk, persisting after comprehensive confounder adjustment. These findings underscore MASLD’s potential role in gout pathogenesis and highlight the clinical relevance of targeted MASLD interventions for gout prevention. Mechanistic and causal investigations remain warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic dysfunction-associated fatty liver disease and the risk of gout: a UK Biobank prospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月28日

查看全文
  • Xin Liu,
  • Yi Wang,
  • Hui Song,
  • Zi-bin Tian,
  • Yan-gang Wang,
  • Qian Yu,
  • Chang Li,
  • Qinghui Niu,
  • Xiang-jia Zhu,
  • Ying Chen

摘要

Background

Gout, an inflammatory arthritis characterized by monosodium urate crystal deposition, affects 1–4% of the global population and demonstrates strong associations with metabolic syndrome. Metabolic dysfunction-associated fatty liver disease (MASLD), affecting 38% of adults worldwide, represents a multisystem disorder with substantial morbidity and mortality. This first European prospective cohort study systematically examines the association between MASLD and incident gout risk.

Method

Utilizing UK Biobank data (n = 402,083 after exclusions), we conducted a prospective cohort analysis excluding participants with baseline gout, arthritis, hepatitis B/C, alcohol-related liver disease, or events within the initial 2-year follow-up. Cox proportional hazards models evaluated MASLD–gout associations, with Kaplan–Meier curves illustrating cumulative incidence.

Result

MASLD patients exhibited a 71% elevated gout risk versus non-MASLD counterparts (HR = 1.71, 95% CI 1.59–1.83, P < 0.0001). Subgroup analyses revealed consistent associations across demographics, with attenuated risk in older adults (≥ 65 years: HR = 1.55 vs. < 65 years: HR = 1.86). Paradoxically, individuals without diabetes, hypertension, or central obesity demonstrated a higher gout risk than those with these comorbidities. MASLD patients showed significantly greater cumulative gout incidence over time (P < 0.001).

Conclusion

MASLD independently associates with increased gout risk, persisting after comprehensive confounder adjustment. These findings underscore MASLD’s potential role in gout pathogenesis and highlight the clinical relevance of targeted MASLD interventions for gout prevention. Mechanistic and causal investigations remain warranted.